Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
University of Florida
University of Michigan Rogel Cancer Center
University of Leipzig
University of Kentucky
Washington University School of Medicine
Rush University Medical Center
Fred Hutchinson Cancer Center
Rush University Medical Center
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Brown University
University of Florida
M.D. Anderson Cancer Center
Massachusetts General Hospital
Emory University
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
University of Miami
Acute Leukemia French Association
Fred Hutchinson Cancer Center
Columbia University
Northwestern University
University of Cincinnati